Ligand Historical Financial Ratios
| LGND Stock | USD 122.23 6.56 5.67% |
Ligand Pharmaceuticals is lately reporting on over 113 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 72.54 will help investors to properly organize and evaluate Ligand Pharmaceuticals financial condition quickly.
Ligand |
About Ligand Financial Ratios Analysis
Ligand PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Ligand Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Ligand financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Ligand Pharmaceuticals history.
Ligand Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Ligand Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Ligand Pharmaceuticals sales, a figure that is much harder to manipulate than other Ligand Pharmaceuticals Incorporated multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Ligand Pharmaceuticals Incorporated dividend as a percentage of Ligand Pharmaceuticals stock price. Ligand Pharmaceuticals dividend yield is a measure of Ligand Pharmaceuticals stock productivity, which can be interpreted as interest rate earned on an Ligand Pharmaceuticals investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Most ratios from Ligand Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Ligand Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At present, Ligand Pharmaceuticals' Book Value Per Share is projected to increase significantly based on the last few years of reporting. The current year's Free Cash Flow Yield is expected to grow to 0.05, whereas Days Sales Outstanding is forecasted to decline to 72.54.
| 2024 | 2025 (projected) | Dividend Yield | 0.48 | 0.42 | Price To Sales Ratio | 11.73 | 9.21 |
Ligand Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Ligand Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ligand Pharmaceuticals fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Price To Sales Ratio | 8.63 | 9.27 | 5.74 | 9.41 | 11.73 | 9.21 | |
| Ptb Ratio | 2.27 | 3.13 | 1.89 | 1.76 | 2.36 | 4.46 | |
| Days Sales Outstanding | 115.64 | 120.7 | 65.17 | 109.27 | 83.81 | 72.54 | |
| Book Value Per Share | 43.84 | 49.41 | 35.42 | 40.52 | 45.4 | 47.67 | |
| Free Cash Flow Yield | 0.0311 | 0.0273 | 0.11 | (0.003458) | 0.0486 | 0.051 | |
| Operating Cash Flow Per Share | 3.37 | 4.74 | 8.17 | 2.87 | 5.31 | 5.57 | |
| Stock Based Compensation To Revenue | 0.0829 | 0.2 | 0.16 | 0.14 | 0.31 | 0.25 | |
| Capex To Depreciation | 0.16 | 0.17 | 0.35 | 0.0988 | 0.0537 | 0.051 | |
| Pb Ratio | 2.27 | 3.13 | 1.89 | 1.76 | 2.36 | 4.46 | |
| Ev To Sales | 10.82 | 10.41 | 6.19 | 9.28 | 11.34 | 9.55 | |
| Free Cash Flow Per Share | 3.1 | 4.21 | 7.11 | (0.25) | 5.21 | 5.47 | |
| Roic | 0.001906 | 0.0762 | 0.004986 | 0.0131 | (0.0899) | (0.0944) | |
| Inventory Turnover | 1.15 | 2.28 | 3.97 | 1.46 | 1.32 | 1.25 | |
| Net Income Per Share | 33.13 | (0.18) | 3.44 | (0.31) | 3.02 | 0.5 | |
| Days Of Inventory On Hand | 317.82 | 160.42 | 91.85 | 249.61 | 287.05 | 156.49 | |
| Payables Turnover | 8.04 | 7.4 | 9.95 | 14.44 | 13.0 | 13.65 | |
| Research And Ddevelopement To Revenue | 0.46 | 0.32 | 0.25 | 0.18 | 0.13 | 0.12 | |
| Capex To Revenue | 0.0239 | 0.0316 | 0.0913 | 0.0268 | 0.0109 | 0.0104 | |
| Cash Per Share | 25.41 | 20.51 | 0.0126 | 9.85 | 14.01 | 8.15 | |
| Pocfratio | 29.49 | 32.6 | 8.17 | 24.92 | 20.19 | 19.18 | |
| Interest Coverage | 0.31 | 4.21 | (14.18) | 18.2 | 16.38 | 17.2 | |
| Capex To Operating Cash Flow | 0.0817 | 0.11 | 0.13 | 0.071 | 0.0188 | 0.0178 | |
| Pfcf Ratio | 32.11 | 36.68 | 9.4 | (289.19) | 20.58 | 21.61 | |
| Days Payables Outstanding | 45.4 | 49.33 | 36.67 | 25.27 | 22.75 | 21.61 | |
| Income Quality | (18.29) | 1.38 | (4.13) | 0.95 | (24.07) | (22.87) | |
| Roe | (0.004207) | 0.0695 | (0.008735) | 0.0744 | 0.0109 | 0.0104 | |
| Ev To Operating Cash Flow | 36.94 | 36.62 | 8.81 | 24.58 | 19.52 | 18.55 | |
| Pe Ratio | (539.23) | 44.96 | (215.9) | 23.69 | 216.12 | 226.93 | |
| Ev To Free Cash Flow | 40.23 | 41.2 | 10.13 | (285.26) | 19.9 | 20.89 | |
| Earnings Yield | (0.001855) | 0.0222 | (0.004632) | 0.0422 | 0.004627 | 0.004858 | |
| Intangibles To Total Assets | 0.22 | 0.58 | 0.57 | 0.6 | 0.39 | 0.32 | |
| Net Debt To E B I T D A | 5.89 | 2.38 | 1.61 | (0.17) | 2.88 | 3.03 | |
| Current Ratio | 5.0 | 11.15 | 2.67 | 14.15 | 8.93 | 4.74 | |
| Tangible Book Value Per Share | (5.34) | 4.6 | 8.25 | 13.33 | 25.07 | 26.32 | |
| Receivables Turnover | 3.16 | 3.02 | 5.6 | 3.34 | 4.36 | 6.97 | |
| Graham Number | 13.49 | 61.8 | 15.7 | 52.43 | 22.51 | 23.91 | |
| Shareholders Equity Per Share | 43.84 | 49.41 | 35.42 | 40.52 | 45.4 | 47.67 | |
| Debt To Equity | 0.64 | 0.41 | 0.15 | 0.008796 | 0.008556 | 0.008128 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.032 | Earnings Share (0.22) | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.